Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
25
06
2018
revised:
16
08
2018
accepted:
05
10
2018
pubmed:
7
12
2018
medline:
24
12
2019
entrez:
4
12
2018
Statut:
ppublish
Résumé
The fasting-state serum bile acid profile in nonalcoholic fatty liver disease (NAFLD) has been reported to differ when nonalcoholic steatohepatitis is compared to nonalcoholic fatty liver. However, there are few data comparing changes in NAFLD vs non-NAFLD, or whether the bile acid profile differs according to the degree of fibrosis. To examine the serum bile acid profile across the entire spectrum of NAFLD. We performed a cross-sectional analysis of two complementary cohorts: a Twin and Family cohort of 156 participants, and a biopsy-proven-NAFLD cohort of 156 participants with fasting bile acid profiling using liquid chromatography/mass spectrometry. In the Twin and Family cohort (mean age 46.3 years and body mass index (BMI) 26.6 kg/m Fasting-state serum bile acid profile alterations are seen across the entire spectrum of NAFLD. The total serum bile acids did not differ significantly between NAFLD vs non-NAFLD and nonalcoholic fatty liver vs nonalcoholic steatohepatitis, but were significantly perturbed progressively as liver fibrosis increases.
Sections du résumé
BACKGROUND
The fasting-state serum bile acid profile in nonalcoholic fatty liver disease (NAFLD) has been reported to differ when nonalcoholic steatohepatitis is compared to nonalcoholic fatty liver. However, there are few data comparing changes in NAFLD vs non-NAFLD, or whether the bile acid profile differs according to the degree of fibrosis.
AIM
To examine the serum bile acid profile across the entire spectrum of NAFLD.
METHODS
We performed a cross-sectional analysis of two complementary cohorts: a Twin and Family cohort of 156 participants, and a biopsy-proven-NAFLD cohort of 156 participants with fasting bile acid profiling using liquid chromatography/mass spectrometry.
RESULTS
In the Twin and Family cohort (mean age 46.3 years and body mass index (BMI) 26.6 kg/m
CONCLUSIONS
Fasting-state serum bile acid profile alterations are seen across the entire spectrum of NAFLD. The total serum bile acids did not differ significantly between NAFLD vs non-NAFLD and nonalcoholic fatty liver vs nonalcoholic steatohepatitis, but were significantly perturbed progressively as liver fibrosis increases.
Identifiants
pubmed: 30506692
doi: 10.1111/apt.15035
pmc: PMC6319963
mid: NIHMS992443
doi:
Substances chimiques
Bile Acids and Salts
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Twin Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-193Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK090303
Pays : United States
Organisme : NCRR NIH HHS
ID : KL2 RR031978
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK106419
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001442
Pays : United States
Informations de copyright
© 2018 John Wiley & Sons Ltd.
Références
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Anal Chem. 2009 Aug 15;81(16):6656-67
pubmed: 19624122
Hepatology. 2018 Aug;68(2):787
pubmed: 29604219
Hepatology. 2018 Apr;67(4):1348-1359
pubmed: 29108123
Mol Cell. 1999 May;3(5):543-53
pubmed: 10360171
Hepatology. 2017 Jan;65(1):350-362
pubmed: 27358174
Gut. 2016 Sep;65(9):1546-54
pubmed: 26002934
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90
pubmed: 24042449
Hepatology. 2012 Sep;56(3):922-32
pubmed: 22431131
Hepatology. 2018 Feb;67(2):534-548
pubmed: 28696585
Nature. 2013 Jul 4;499(7456):97-101
pubmed: 23803760
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
Gastroenterology. 2016 Jun;150(8):1745-1755.e3
pubmed: 26948887
Cell Metab. 2017 May 2;25(5):1054-1062.e5
pubmed: 28467925
Nature. 2012 Feb 01;482(7384):179-85
pubmed: 22297845
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40
pubmed: 24768810
Dig Dis Sci. 2015 Nov;60(11):3318-28
pubmed: 26138654
Gut. 2018 Oct;67(10):1881-1891
pubmed: 28774887
Hepatology. 2018 Feb;67(2):464-466
pubmed: 28926117
Science. 1999 May 21;284(5418):1362-5
pubmed: 10334992
Hepatology. 2013 Apr;57(4):1394-406
pubmed: 23299969
J Hepatol. 2013 May;58(5):949-55
pubmed: 23333527
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Gastroenterology. 2019 Jan;156(1):88-95.e5
pubmed: 30222962
Gastroenterology. 2017 May;152(7):1679-1694.e3
pubmed: 28214524
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Aliment Pharmacol Ther. 2012 Jul;36(1):22-9
pubmed: 22554256
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Diabetes. 2013 Dec;62(12):4184-91
pubmed: 23884887
Hepatology. 2018 Sep;68(3):918-932
pubmed: 29572891
Nat Rev Endocrinol. 2014 Aug;10(8):488-98
pubmed: 24821328
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
Hepatology. 2016 Nov;64(5):1547-1558
pubmed: 27315352
Gastroenterology. 1971 Apr;60(4):491-8
pubmed: 5554239
Eur J Gastroenterol Hepatol. 2011 May;23(5):382-8
pubmed: 21448070
J Med Chem. 2002 Aug 15;45(17):3569-72
pubmed: 12166927
Metabolism. 2011 Mar;60(3):404-13
pubmed: 20423748
Mol Pharmacol. 2007 Nov;72(5):1380-90
pubmed: 17724089
Pharmacol Res. 2016 Feb;104:9-21
pubmed: 26706784
PLoS One. 2016 May 20;11(5):e0151829
pubmed: 27203081
Eur J Gastroenterol Hepatol. 2008 Jun;20(6):519-25
pubmed: 18467911
J Clin Invest. 2017 Jun 30;127(7):2697-2704
pubmed: 28628033
Am J Pathol. 2011 Jan;178(1):175-86
pubmed: 21224055
Gut Microbes. 2013 Sep-Oct;4(5):382-7
pubmed: 23851335
Medicine (Baltimore). 2016 Mar;95(10):e2778
pubmed: 26962776
Science. 1999 May 21;284(5418):1365-8
pubmed: 10334993
Gastroenterology. 2015 Dec;149(7):1784-93
pubmed: 26299412
Aliment Pharmacol Ther. 2013 Mar;37(6):630-9
pubmed: 23383649
Gastroenterology. 2017 Feb;152(3):598-607.e2
pubmed: 27911262
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
J Cheminform. 2010 Oct 18;2(1):9
pubmed: 20955607
Toxicol Appl Pharmacol. 2013 Apr 15;268(2):132-40
pubmed: 23391614
J Hepatol. 2016 Aug;65(2):369-76
pubmed: 27151177